News | Antiplatelet and Anticoagulation Therapies | November 14, 2016

Study Finds Blood Clot Prevention Medications Equally Safe and Effective for PCI Patients

Results find rates of major bleeding and other adverse events statistically similar with bivalirudin versus heparin with short-term tirofiban infusion

bivalirudin, heparin, blood clot prevention medication, PCI, percutaneous coronary intervention, Intermountain study, AHA Scientific Sessions

November 14, 2016 — Two differing blood clot prevention medications are just as safe and effective for patients undergoing percutaneous coronary intervention (PCI), according to a new study.

The scientific community has proposed both medications as potentially superior to longer-term anticoagulation treatments for patients undergoing the non-surgical procedure to open blood vessels narrowed by plaque buildup.

The new study by researchers from the Intermountain Medical Center Heart Institute in Salt Lake City sought to discover which of the two short-term treatment methods —using the drug heparin combined with a short-term (less than six hours) infusion of tirofiban, or short-term periprocedural bivalirudin, another medication that helps prevent blood clots during the procedure — was more effective.

Through this observational study of patients undergoing successful elective PCI, the Intermountain researchers found the risk after 30 days of major bleeding, and one-year risk of death, heart attack and urgent repeat PCI, was low and not significantly different between the two treatment methods.

Results of the study were presented during the American Heart Association Scientific Sessions, Nov. 12-16 in New Orleans.

“Bivalirudin has been considered the gold standard for reducing bleeding during percutaneous coronary intervention, but our study shows heparin plus short-term tirofiban is just as good and possibly better,” said Intermountain Medical Center Heart Institute cardiologist J. Brent Muhlestein, M.D., the lead author on the study. “The results certainly justify a randomized clinical trial to explore identified trends.”

Researchers studied results from patients who underwent PCI between January 2013 and December 2015. Of the 857 patients enrolled in the study, 402 received heparin plus short-term tirofiban treatment and 455 received bivalirudin. The patients were between the ages of 51 and 78.

There was a slight reduction in major bleeding and death with the use of heparin plus short-term tirofiban over bivalirudin alone, but due to the overall low incidence of adverse events, the difference did not reach statistical significance.

The 30-day incidence of TIMI (Thrombolysis in Myocardial Infarction) major bleeding score was 1.2 percent for patients treated with heparin and tirofiban and 3.1 percent for bivalirudin patients.

In addition to Muhlestein, other members of the Intermountain Medical Center Heart Institute research team include: Heidi T. May, Ph.D.; Tami L. Bair; Viet Le, PA-C; Jeffrey L. Anderson, M.D.; Brian Whisenant, M.D.; Kirk U. Knowlton, M.D.; and Donald L. Lappé, M.D.

For more information: www.scientificsessions.org

Related Content

Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S.
PhaseBio Receives FDA Breakthrough Therapy Designation for Ticagrelor Reversal Agent
Technology | Antiplatelet and Anticoagulation Therapies | April 30, 2019
PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people sto
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer...
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for...
Overlay Init